Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1963 Target Snapshot

Thyrotropin receptor · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
17,152Compounds
33Assays
0Approved Drugs
122.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-15

Thyrotropin receptor shows approved-linked disease relevance led by papillary thyroid carcinoma. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P16473. Start with papillary thyroid carcinoma, then reuse UniProt P16473 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with papillary thyroid carcinoma, then reuse UniProt P16473 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-15 2 linked drugs
Open source guide
Disease program
papillary thyroid carcinoma

Thyrotropin receptor shows approved-linked disease relevance led by papillary thyroid carcinoma. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with papillary thyroid carcinoma because it currently carries approved-linked support. Linked drugs include THYROTROPIN, THYROTROPIN ALFA. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Thyrotropin receptor as ChEMBL target CHEMBL1963, mapped to UniProt P16473. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Thyrotropin receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-15
ChEMBL target ID
CHEMBL1963
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-15
www.ebi.ac.uk
UniProt accession
P16473
Thyrotropin receptor
UniProt accession via ChEMBL component mapping As of 2026-09-15
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-15
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Thyrotropin receptor is the right protein anchor across sources, using UniProt P16473 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why papillary thyroid carcinoma is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameThyrotropin receptor
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP16473
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelThyrotropin receptor
UniProt AccessionP16473
Component TypeProtein
Sequence Length764 aa

Thyrotropin receptor

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Thyrotropin receptor, mapped to UniProt P16473. Sequence length is 764 aa.

Mapped IDP16473
Review nameThyrotropin receptor
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Thyrotropin receptor shows approved-linked disease relevance led by papillary thyroid carcinoma. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
papillary thyroid carcinoma
2 linked drugs · 2 direct · 2 efficacy
Linked drugTHYROTROPIN
Linked drugTHYROTROPIN ALFA
Approved-linked Approved
thyroid cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugTHYROTROPIN ALFA
Approved-linked Approved
thyroid carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugTHYROTROPIN ALFA
Approved-linked Approved
thyroid neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugTHYROTROPIN ALFA
Late clinical Phase III
head and neck malignant neoplasia
1 linked drug · 1 direct · 1 efficacy
Linked drugTHYROTROPIN
Clinical signal Phase II
follicular thyroid carcinoma
2 linked drugs · 2 direct · 2 efficacy
Linked drugTHYROTROPIN
Linked drugTHYROTROPIN ALFA
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with papillary thyroid carcinoma because it currently carries approved-linked support. Linked drugs include THYROTROPIN, THYROTROPIN ALFA. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasepapillary thyroid carcinoma
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Assay Mix

Activity Type Distribution

IC5072.0
EC5050.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5618835 8.38 EC50 4.2 Preclinical
CHEMBL5618807 8.08 EC50 8.3 Preclinical
CHEMBL5281228 7.96 IC50 11.0 Preclinical
CHEMBL5618086 7.96 IC50 11.0 Preclinical
CHEMBL5620176 7.94 EC50 11.6 Preclinical
CHEMBL3897841 7.92 IC50 12.0 Preclinical
CHEMBL1715624 7.75 EC50 18.0 Preclinical
CHEMBL5275472 7.62 IC50 24.0 Preclinical
CHEMBL5267043 7.48 IC50 33.0 Preclinical
CHEMBL5287707 7.46 IC50 35.0 Preclinical
Distribution

pChEMBL Value Distribution

8
5.0
6
5.5
10
6.0
7
6.5
32
7.0
7
7.5
3
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

33
Total Assays
47
Tested Compounds
2
Assay Types
Functional — 24 assays, 47 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 12 3 7.1
cell-based format 12 44 6.5
Binding — 9 assays, 26 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 5 2 4.8
cell-based format 4 24 7.2

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine